🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

India's pharma exports clock double-digit growth amid surging demand in US, UK

Published 18-06-2024, 06:27 pm
© Reuters.  India\'s pharma exports clock double-digit growth amid surging demand in US, UK
USD/INR
-
RDY
-
CIPL
-
REDY
-
SUN
-

New Delhi, June 18 (IANS) India’s pharmaceutical exports continue to register double-digit growth, reflecting the strong demand for the country’s affordable generic medicines in global markets led by the USA and UK.India’s pharma exports grew by 10.45 per cent in May this year to touch the $2.3 billion mark compared with the $2.08 billion in the same month of the previous financial year.

“It is moving in a positive way and we are optimistic of sustaining growth of not less than 10 per cent,” Director General, Pharmaceuticals Export Promotion Council of India, Ravi Uday Bhaskar said on the quick estimate numbers released last week by the Centre.

India is now the world's third-largest drugmaker by volume amid the growing demand for the country’s pharmaceutical products in export markets.

The US is a key market, which accounts for about 30 per cent of India's annual pharma exports after a nearly 16 per cent increase in fiscal 2024, according to Pharmexcil.

The country's drug shortages as well as the increased use of drugs for lifestyle diseases such as diabetes, hypertension and depression is expected to fuel the demand for India's affordably priced drugs, according to Bhaskar.

According to a report by India Ratings and Research, Indian drugmakers will sustain their revenue improvement in 2024-2025 due to drug shortages in the United States. India is a hub of bulk generic drug manufacturing and drugmakers including Dr Reddy's, Cipla (NS:CIPL), Sun Pharma (NS:SUN) derive a significant share of revenue from both the US and Europe.

The world's largest drug market is facing decade-high drug shortages, India Ratings said in a note citing data from with Utah Drug Information Service.

There is an active shortage of 233 drugs across 22 therapeutic categories as of April, led mainly by discontinuing production of some drugs, rising demand and delays in shipments, it said, also citing data from the US Food and Drug Administration.

--IANS

sps/uk

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.